Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

Reynolds, Catherine J.; Pade, Corinna; Gibbons, Joseph M.; Butler, David K.; Otter, Ashley D.; Menacho, Katia; Fontana, Marianna; Smit, Angelique; Sackville-West, Jane E.; Cutino-Moguel, Teresa; Maini, Mala K.; Chain, Benjamin; Noursadeghi, Mahdad; Brooks, Tim; Semper, Amanda; Manisty, Charlotte; Treibel, Thomas A.; Moon, James C.; Valdes, Ana M.; McKnight, Áine; Altmann, Daniel M.; Boyton, Rosemary

SARS-CoV-2 vaccine rollout has coincided with the spread of variants of concern. We investigated if single dose vaccination, with or without prior infection, confers cross protective immunity to variants. We analyzed T and B cell responses after first dose vaccination with the Pfizer/BioNTech mRNA vaccine BNT162b2 in healthcare workers (HCW) followed longitudinally, with or without prior Wuhan-Hu-1 SARS-CoV-2 infection. After one dose, individuals with prior infection showed enhanced T cell immunity, antibody secreting memory B cell response to spike and neutralizing antibodies effective against B.1.1.7 and B.1.351. By comparison, HCW receiving one vaccine dose without prior infection showed reduced immunity against variants. B.1.1.7 and B.1.351 spike mutations resulted in increased, abrogated or unchanged T cell responses depending on human leukocyte antigen (HLA) polymorphisms. Single dose vaccination with BNT162b2 in the context of prior infection with a heterologous variant substantially enhances neutralizing antibody responses against variants.